Research Article

RANKL Impairs the TLR4 Pathway by Increasing TRAF6 and RANK Interaction in Macrophages

Ryerson Fonseca Mota,1 Paulo Henrique Cavalcanti de Araújo,1 Maria Eduarda Ramos Cezine,1 Flávia Sayuri Matsuo,1 Rodrigo Jair Morandi Metzner,1 Carlos Alberto Oliveira de Biagi Junior,2 Kamila Chagas Peronni,2 Hiroki Hayashi,3 Munehisa Shimamura,3 Hironori Nakagami,3 and Mariana Kiomy Osako1

1Department of Cell and Molecular Biology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil
2Institute for Cancer Research, Guarapuava, Parana, Brazil
3Department of Health Development and Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

Correspondence should be addressed to Mariana Kiomy Osako; mko@fmrp.usp.br

Received 22 September 2021; Revised 2 March 2022; Accepted 16 March 2022; Published 12 April 2022

Academic Editor: Luca Liberale

Copyright © 2022 Ryerson Fonseca Mota et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

High serum levels of osteoprotegerin (OPG) are found in patients with obesity, type 2 diabetes, sepsis, or septic shock and are associated with a high mortality rate in stroke. The primary known function of OPG is to bind to the receptor activator of NF-κB ligand (RANKL), and by doing so, it inhibits the binding between RANKL and its receptor (RANK). TLR4 signaling in macrophages involves TRAF6 recruitment and contributes to low-grade chronic inflammation in adipose tissue. LPS is a classical activator of the TLR4 pathway and induces the expression of inflammatory cytokines in macrophages. We have previously observed that in the presence of RANKL, there is no LPS-induced activation of TLR4 in macrophages. In this study, we investigated the crosstalk between RANK and TLR4 pathways in macrophages stimulated with both RANKL and LPS to unveil the role of OPG in inflammatory processes. We found that RANKL inhibits TLR4 activation by binding to RANK, promoting the binding between TRAF6 and RANK, lowering TLR4 activation and the expression of proinflammatory mediators. Furthermore, high OPG levels aggravate inflammation by inhibiting RANKL. Our findings elect RANKL as a candidate for drug development as a way to mitigate the impact of obesity-induced inflammation in patients.

1. Introduction

The adipose tissue is an essential endocrine organ that has a central role in obesity-associated complications such as dyslipidemia, insulin resistance, and type 2 diabetes. In obese patients, the adipose tissue consists of adipocytes, preadipocytes, vascular, neural, and immune cells—such as macrophages [1, 2]. These cells secrete a wide range of hormones and cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β), and macrophage chemoattractant protein-1 (MCP-1), which induces macrophage infiltration and low-grade inflammation that eventually results in a global impairment of glucose metabolism and insulin resistance [3].

Osteoprotegerin (OPG) is a soluble protein that lacks transmembrane and cytoplasmic domains. High serum OPG levels have been found in patients with obesity [4] and type 2 diabetes [5], but whether OPG high levels were deleterious or beneficial is unclear.

A previous study reported that patients with sepsis or in septic shock have higher levels of OPG when compared to
This transcription factor, in turn, activates the transcription of IKK and phosphorylation of the TNF-receptor-associated factor 6 (TRAF6), resulting in activation of TLR4. The toll-like receptor 4 (TLR4) [15], an essential part of the innate immune system, can also be activated by endogenous molecules (IFN-γ) and lipopolysaccharide (LPS, a component of the cell wall of gram-negative bacteria) to express IL-1β, TNF-α, and inducible nitric oxide synthase (iNOS), which generates reactive NO species with microbicidal and proinflammatory properties [13, 14]. Macrophage activation by LPS involves the toll-like receptor 4 (TLR4) [15], an essential pattern recognition receptor involved in the innate immune system response. Upon TLR4 binding to LPS, its cytosolic domain interacts with several adaptor proteins, such as TNF-receptor-associated factor 6 (TRAF6), resulting in activation of IKK and phosphorylation of the IκBα, its subsequent ubiquitination, degradation, and release of NF-κB. This transcription factor, in turn, activates the transcription of proinflammatory mediators [16].

TLR4 can also be activated by endogenous molecules released from dying or lysed cells [17]. High-fat diet-induced hypertrophied adipocytes eventually undergo cell lysis in the adipose tissue, releasing large amounts of free fatty acids. These free fatty acids can activate innate immune cells via TLR4 expressed in macrophages, which leads to proinflammatory cytokine expression and adipose tissue inflammation [18]. Pretreatment with RANKL reduces the cytokine storm in LPS-induced septic shock in a murine model by decreasing the expression of adaptor proteins of the TLR4 pathway, such as myeloid differentiation factor 88 (MyD88), IL-1 receptor associated-kinase 1 (IRAK1), and TRAF6 [19]. The latter is an adaptor protein shared by both pathways (RANK and TLR4) [16, 20].

Preliminary observations done by our group suggest that, in the presence of RANKL, there is no LPS-induced activation of TLR4 in macrophages, even though the RNA expression of the adaptor proteins (MyD88, IRAK1, and TRAF6) does not change when compared to the group not submitted to RANKL stimulation (unpublished data). This novel observation led us to raise the hypothesis that an additional mechanism might inhibit activation of the TLR4 pathway in macrophages. Considering that the primary known function of OPG is to bind to RANKL and by doing that OPG inhibits the binding between RANK and its receptor (RANK), in this study, we investigated the crosstalk between RANK and TLR4 pathways in macrophages costimulated with RANKL and LPS, to unveil the role of OPG in inflammatory processes.

2. Material and Methods

2.1. Animal Studies. Animal care and experimentation were performed following the Ethical Principles in Animal Research adopted by the National Council for the Control of Animal Experimentation (CONCEA), and this study was approved under the protocol number 047/2017 by the Animal Care and Use Committee of Ribeirao Preto Medical School of University of Sao Paulo.

The wild-type C57BL/6J (WT) and the B6.129S4-Tnfrsf11b tm1Eac/J (OPG−/−) mice were obtained from Jackson Laboratories. All animals used in this study were 8-week-old male mice. Standard diet (ND) consisted of AIN-93G diet, and the high-fat diet (HFD) consisted of AIN-93G modified to contain 35% lipids (4% soy oil and 31% lard). All mice had access to water and food ad libitum and were housed in the animal facility at 20°C–22°C under a 12h light-dark cycle.

2.2. Histological Analysis. The dissected adipose tissue consisted of visceral white adipose tissue (vWAT) located in the epididymal region and fixed and prepared for histological analysis. Paraffin sections were stained with hematoxylin and eosin (H&E), and the images were taken by Scanscope (Olympus BX61VS).

2.3. Ex Vivo Culture. The ex vivo explant culture was performed as described before [21]. Visceral white adipose tissues were dissected, washed with PBS, and supplemented with penicillin (100 U/ml) and streptomycin (100 μg/ml), cut in small pieces, weighted, distributed in 24-well plates, and cultured in RPMI. The supernatant was collected after 24h, centrifuged, and used as adipose tissue-conditioned medium (ATCM) or centrifuged and stored at -80°C until ELISA assays were performed.

2.4. Enzyme-Linked Immunosorbent Assay (ELISA). IL-1β and TNF-α levels were measured using the 96-well strip plate Quantikine mouse IL-1beta ELISA Kit (R&D Systems, MAB900C) and TNF-alfa ELISA Kit (R&D Systems, MTA00B), respectively.

2.5. Cell Culture. Immortalized monocyte lineages obtained from patients with acute monocytic leukemia (THP-1 cells) from Rio de Janeiro Cell Bank (#0234) were cultivated with RPMI supplemented with 10% of fetal bovine serum (FBS) and penicillin (100 U/ml) and streptomycin (100 μg/ml). The THP-1 cells were seeded at a confluence of 1 × 10⁶ cells on 3.5 cm diameter plates and derived into macrophages by stimulation with PMA (5 ng/ml) for 24h. Subsequently, THP1-derived macrophages were stimulated with recombinant RANKL protein (Peprotech) at 10 ng/ml, LPS (Sigma Aldrich) at 10 ng/ml, or costimulus LPS+RANKL.

2.6. Colocalization Analysis by Immunofluorescence Microscopy. Anti-RANK (H-300, #sc-9072, Santa Cruz Biotechnologies) and anti-TRAF6 (D-10, #sc-8409, Santa Cruz Biotechnologies) were used to label these proteins.
Biotechnologies) were used to label macrophages with their respective secondary antibodies, Alexa Fluor 488 anti-rabbit (#A21042, Invitrogen), and Alexa Fluor 594 anti-mouse (# A21125, Invitrogen). Immunofluorescence images were acquired with a Leica TCS-SP5 confocal microscope (Leica Microsystems). The images were obtained as confocal stacks of ~60 optical sections of 1,024 x 1,024 pixels. Each cell stack was used to generate a colocalization value with background correction, performed in triplicate, and quantified as described before [22]. Fiji (Imagej) was used for image processing, and Manders’ correlation coefficient was used to calculate colocalization on each cell section.

2.7. RT-Quantitative PCR. RNA was extracted from cultured cells with Tri Reagent (Sigma Aldrich) and reverse-transcribed using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The resulting cDNA was analyzed by qPCR using Quantificat SYBR Green (Qiagen). Reactions were performed in 96-well plate format using ABI PRISM 7500 instrument (Applied Biosystems), and relative mRNA levels were calculated through comparative CT normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in each sample. Gene expression data was presented on a logarithmic scale. The sequences of the primer sets were as follows: IL-1β forward CCTGACCTCT CCTACTCACTT and reverse CGGTTCGCATCATCAGAA TGT; TNF-α forward CCGGGATTCAGGAATCTC and reverse GTGAGGGATCAAAGCTGTAG; iNOS forward ACAAGGCTACCCCTCCAGAT and reverse CGGTAGCTGCCGT; and GAPDH forward GGTTGCTCATCAGAATCGT and reverse CTTCGACTTCAACA and reverse CCACAGGAAATGAG CTTGAC.

2.8. Western Blot. Whole-cell extracts were prepared in RIPA buffer containing protease inhibitor cocktail (Roche). The total protein concentration was determined with DC Protein Assay (Bio-Rad Laboratories). Equivalent doses of proteins were then size-fractionated in 10% SDS-PAGE, transferred to a 0.45 μm pore size PVDF Immobilon-P membrane (Millipore), subjected to 5% BSA blockage, and then incubated with the following antibodies: TLR4 (#ab183459, Abcam), RANK (#ab200369, Abcam), TRAF6 (#ab33915, Abcam), and β-actin (#sc-81178, Santa Cruz Biotechnologies). The bound antibodies were detected by the respective horseradish peroxidase-conjugated anti-IgG antibody (Amersham Biosciences) followed by ECL detection system (Amersham Biosciences) according to the manufacturer’s instructions.

2.9. Co-Immunoprecipitation Assays. Whole-cell extracts were prepared in RIPA lysis buffer containing protease inhibitor cocktail (Roche), and lysis was reinforced using a syringe with a 0.33 x 13 mm needle. The total protein concentration was determined with DC Protein Assay (Bio-Rad Laboratories). An equivalent amount of proteins (750 μg/sample) was incubated with a rabbit primary antibody anti-TRAF6 (#ab33915, Abcam) for 3 h at 4°C. Streptavidin magnetic sepharose beads (#GE28, GE Healthcare Life Sciences) were incubated with a biotin-conjugated anti-rabbit IgG antibody (#ab64257, Abcam) for 2 h at 4°C. After washing, magnetic beads were mixed with the proteins, incubated with the primary antibody overnight at 4°C, and eluted. The purified protein concentration was determined with DC Protein Assay (Bio-Rad Laboratories) and followed with western blot assays (2 μg/well) to analyze TRAF6 interaction with RANK and TLR4.

2.10. Transfection and Luciferase Assays. A population of 1 × 10⁶ THP-1-derived macrophages were seeded on a 3.5 cm plate and transfected using Lipofectamine® 2000 (2 μl/ml) (Invitrogen) diluted in Opti-MEM (Gibco) with 5 μg of the luciferase reporter plasmid regulated by NF-κB, pNFκB-Luc (#631745, Clontech) or a plasmid expressing human RANK point mutated, pcDN3A-human-RANKΔ, in a final volume of 1 ml per plate. The cells were transfected for 5 h, and the medium was replaced with 1 ml of supplemented RPMI. After 24 h, the cells were stimulated with recombinant RANKL, LPS, or costimulus LPS+RANKL for 24 h. The pcDN3A-human-RANKΔ plasmid was constructed by using a pcDNA3 template and insertion of the human RANK sequence (NCBI GenBank AF018253.1) point mutated at TRAF6 binding sites, 344-349 PTEDEY, 377-382 PLEVGE, and 453-458 PGEDHE by the substitution of glutamic acid (E) for alanine (A) in residues 346, 379, and 455. Luciferase activity was quantified according to the manufacturer’s instructions (Promega). Briefly, the cells were collected and lysed, and an equivalent protein concentration was incubated in the presence of luciferin substrate. The luminescence was measured using a 96-well plate, and data were shown as CPS—counts per second.

2.11. RNA Isolation from Bone Marrow-Derived Macrophages. Bone marrow-derived macrophages were collected from the femur and tibia of wild-type mice and cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, and macrophage colony-stimulating factor (M-CSF, 20 ng/ml). After 7 days, the attached cells were stimulated with RANKL (10 ng/ml) for 24h. RNA was extracted from cultured cells with Tri Reagent (Sigma), RNA quality was checked with an Agilent TapeStation (Agilent Technologies, Inc.), and all RINs were between 7.7 and 9.1.

2.12. Library Preparation and Deep Sequencing. Library preparation was performed according to the manufacturer’s protocol using the Illumina Stranded mRNA Sample Preparation Kit. Briefly, the extracted RNA was quantified using Qubit assays (Life Technologies, USA) to ensure an adequate RNA concentration (500 ng), followed by polyA mRNA selection and fragmentation, first and second strand synthesis, adenylation of 3’ ends, and index adapter ligation. Each library was subjected to 15 cycles of PCR amplification, and the size distribution was examined on an Agilent TapeStation (Agilent Technologies, Inc.) using a D1000 ScreenTape. All libraries displayed a band between 200 and 500 bp with a peak at approximately 330 bp. The libraries were quantified with Qubit 2.0 Fluorometer (Life Technologies, Inc.), loaded at a concentration of 2.3 nM with 15 libraries, pooled, and...
sequenced on Illumina NovaSeq Sequencing System with paired-end 150 bp reads.

2.13. Mapping of RNA-Seq Libraries and Differential Expression Analysis. The bcl files generated by the sequencer were converted to fastq using the software bcl2fastq (v2.20.0.422). Based on the fastq files, data quality control was performed using FastQC, followed by alignment and mapping of the reads against the reference genome (GRCh38.101) and counting using RSEM software (v1.3.1), and the alignment file was sorted using samtools (v1.11). All individual count files per sample were aggregated, thus having a single count matrix. Differential expression analysis was performed using DESeq2 package (v1.30.1), and the functional enrichment was performed using the clusterProfiler package (v3.18.1). The plots were generated using ggplot2 (v3.3.3) and ComplexHeatmap (2.6.2) packages in R (v4.0.5).

2.14. Statistical Analysis. All data were presented as SEM analyzed using GraphPad Prism v. 7.0 (San Diego, CA, USA). Statistical significance was determined by either one-way ANOVA followed by Bonferroni’s posttest or unpaired two-tailed Student’s t-test. Significance presented as p < 0.05, p < 0.01, and p < 0.0001.

3. Results

3.1. RANKL Reduces Inflammation in Adipose Tissue and Macrophages. Adipose tissues from obese animals and humans also show leucocyte infiltration in visceral white adipose tissue (vWAT) due to adipocyte hypertrophy and eventual release of intracellular components during cell lysis [23, 24]. Free fatty acids, for example, are recognized by TLR4 in macrophages that form crown-like structures [23, 24]. Adipose tissues from obese animals and humans also show leucocyte infiltration in visceral white adipose tissue (vWAT) due to adipocyte hypertrophy and eventual release of intracellular components during cell lysis [23, 24]. RANKL, as shown by immunofluorescence (Figure 3(a)). Interestingly, the colocalization degree was the same in RANKL alone and LPS+RANKL costimulated cells (Figure 3(b)). To confirm an existing interaction between RANK and TRAF6, protein extracts of macrophages stimulated for 10 min with LPS, RANKL, or both were co-immunoprecipitated with a TRAF6 antibody. As expected, RANK coprecipitates with TRAF6 under RANKL stimulation, which is not observed in the group stimulated with LPS only (Figure 3(c)). However, higher RANK levels were bound to TRAF6 in cells under LPS+RANKL costimulation (Figure 3(c)). Conversely, lower levels of TLR4 have bound to TRAF6 in LPS+RANKL costimulated THP1 macrophages if compared to the LPS group (Figure 3(d)) and the total level of TRAF6 (Figure 3(e)). Therefore, TRAF6 binds to RANK under the presence of RANKL and LPS, which impairs the TLR4 pathway activation.

3.2. RANKL Lowers LPS Response in Macrophages. LPS is a classical activator of the TLR4 pathway and induced macrophages into a higher inflammatory cytokine expression profile that included IL-1β and TNF-α expression, but not when costimulated with RANKL (Figures 2(a)–2(d)). Accordingly, macrophages stimulated with RANKL and LPS showed lower expression of iNOS when compared to the LPS group, as quantified by immunofluorescence (Figures 2(e) and 2(f)) and expression of mRNA level (Figure 2(g)). Activation of TLR4 pathway culminates in IkBα phosphorylation (phospho-IkBα), which is ubiquitinated, undergoes proteasome degradation, and releases NFκB. Accordingly, THP1 macrophages expressing NFκB-driven luciferase reporter gene showed increased luciferase activity under LPS stimulation, but it decreased under LPS+RANKL costimulation (Figure 2(h)). These data indicate that similar to the response elicited by adipose tissue-conditioned medium, RANKL decreased the LPS-induced response in macrophages, suggesting that RANK activation impairs the TLR4 signaling pathway in a way that anticipates NF-κB activation.

3.3. RANKL Promotes TRAF6 and RANK Interaction in Detriment to TLR4 in LPS-Induced Macrophages. RANKL activates the receptor RANK to elicit a cellular response, a process that depends on TRAF6, which is also involved in the TLR4 activation pathway [25]. Macrophages stimulated with RANKL showed marked colocalization of RANK and TRAF6, as shown by immunofluorescence (Figure 3(a)). Interestingly, the colocalization degree was the same in RANKL alone and LPS+RANKL costimulated cells (Figure 3(b)). To confirm an existing interaction between RANK and TRAF6, protein extracts of macrophages stimulated for 10 min with LPS, RANKL, or both were co-immunoprecipitated with a TRAF6 antibody. As expected, RANK coprecipitates with TRAF6 under RANKL stimulation, which is not observed in the group stimulated with LPS only (Figure 3(c)). However, higher RANK levels were bound to TRAF6 in cells under LPS+RANKL costimulation (Figure 3(c)). Conversely, lower levels of TLR4 have bound to TRAF6 in LPS+RANKL costimulated THP1 macrophages if compared to the LPS group (Figure 3(d)) and the total level of TRAF6 (Figure 3(e)). Therefore, TRAF6 binds to RANK under the presence of RANKL and LPS, which impairs the TLR4 pathway activation.

3.4. RANKL Inhibits LPS-Induced Cytokine Expression upon TRAF6/RANK Binding. RANK interaction with TRAF6 is essential for RANKL signaling in osteoclasts as TRAF6-/mice show severe osteopetrosis [20]. As RANK interacts with TRAF6 with 3 domains (residues 344–349, 377–382, and 453–458) [26], a mutated version of RANK (RANKΔ) was generated by the substitution of glutamic acid (E) for alanine (A) in residues 346, 379, and 455 (Figure 4(a)) and transfected into macrophages (Figure 4(b)) to investigate the relevance of RANK/TRAF6 binding in the anti-inflammatory response of RANKL. The overexpression of RANKΔ abrogated the effect of RANKL in LPS-induced expression of IL-1β and TNF-α (Figures 4(c) and 4(d)). Thus, RANK/TRAF6 binding is essential for RANKL inhibition in LPS-induced TLR4 activation.

3.5. RANKL Downregulates the Pathways Related to Chemotaxis in BMDM. To confirm the global effect of RANKL in inhibiting inflammatory responses in
Figure 1: RANKL reduces inflammation in adipose tissue and macrophages. (a) Representative images of H.E.-stained visceral white adipose tissue (vWAT) from wild-type (WT) mice showing increased cell infiltration and crown-like structure formation (inset image) compared to OPG-/- mice under a high-fat diet for 3 months. (b) Interleukin-1β (IL-1β) level in the supernatant of vWAT from a 3-month high-fat diet-fed WT and OPG-/- mice cultured ex vivo for 24 h and detected by ELISA, n = 6, *p < 0.05 vs. WT. (c) Representative images of macrophages immunostained to detect iNOS (magenta), F4/80 (green), and nuclei (DAPI, blue) by immunofluorescence in THP1 macrophages with culture medium (CT), stimulated with RANKL (10 ng/ml), and adipose tissue-conditioned medium (ATCM) with or without RANKL (10 ng/ml) (ATCM+RANKL) for 24 h. (d) Quantification of iNOS positive cells in CT, RANKL, ATCM, and ATCM+RANKL groups. The quantification was based on the threshold measured in 6 fields of each sample by ImageJ software (n = 40). (e) Quantification of relative iNOS mRNA expression in ATCM, RANKL, and ATCM+RANKL stimulated THP1 macrophages for 24 h, detected by qPCR, and compared to the nonstimulated control group (CT). (f) IL-1β and TNF-α expression in bone marrow-derived macrophages stimulated with ATCM and RANKL (10 ng/ml) for 24 h detected by qPCR and compared to the nonstimulated control group (CT). *p < 0.01 vs. CT and #p < 0.01 vs. ATCM. All data are presented as means ± SD.
Figure 2: RANKL lowers LPS response in macrophages. (a and b) IL-1β and TNF-α expression in THP1 macrophages stimulated with LPS (10 ng/ml) and RANKL (10 ng/ml) or costimulated with both (LPS+RANKL) for 24 h, detected by qPCR, and compared to the nonstimulated control group (CT). (c and d) IL-1β and TNF-α protein level in supernatant of THP1 macrophages stimulated with LPS (10 ng/ml) and RANKL (10 ng/ml) or costimulated with both (LPS+RANKL) for 24 h and detected by ELISA. (e) Representative images of macrophages immunostained to detect iNOS (magenta), F4/80 (green), and nuclei (DAPI, blue) by immunofluorescence in THP1 macrophages stimulated with LPS (10 ng/ml) and RANKL (10 ng/ml) or costimulated with both (LPS+RANKL) for 24 h. (f) Quantification of iNOS positive cells in LPS and RANKL stimulated THP1 macrophages. The quantification was based on the threshold in 6 fields of each sample by ImageJ software (n = 4). (g) Quantification of relative iNOS mRNA expression in THP1 macrophages stimulated with LPS and RANKL or costimulated with both (LPS+RANKL) for 24 h, detected by qPCR, and compared to the nonstimulated control group (CT). (h) Quantification of NF-κB activation in THP1 macrophages transfected with a plasmid expressing NF-κB-driven luciferase stimulated with LPS (10 ng/ml) and RANKL (10 ng/ml) or costimulated with both (LPS+RANKL) for 24 h and detected by luciferase activity presented as relative units (RU). A one-way ANOVA followed by Bonferroni’s multiple comparisons test was performed to compare all groups (*p < 0.01 vs. CT and #p < 0.01 vs. LPS). The data represent the mean of three independent experiments and are presented as means ± SD.
macrophages, BMDMs collected from WT mice and stimulated for 24 h with RANKL showed a differential expression of 376 transcripts (Figure 5(a)). In functional enrichment analysis (Figure 5(b)), RANKL stimulation downregulated the expression of genes related to chemotaxis in proinflammatory macrophages, such as Ccl6, Ccl7, and Ccr2, and upregulated the expression of genes related to inorganic ion transport, such as Slc4a8 and Kcnf1 [27, 28] and also downregulated Bmp1, a metalloprotease that activates transforming growth factor-β [29]. Even though the transcript for Tnfsf13b, related to osteoclastogenesis [30], was upregulated by RANKL stimulation, macrophages stimulated with RANKL showed no multicellularity or TRAP activity, markers for osteoclast differentiation (data not shown). Taken together, RANKL stimulation for 24 h downregulates the expression of genes related to chemotaxis of proinflammatory macrophages without inducing osteoclastogenesis.

4. Discussion

In the present study, we have shown that RANKL inhibits TLR4 activation in macrophages by binding to RANK, promoting the binding between TRAF6 (crucial for TLR4 activation) and RANK, affecting events occurring upstream of NF-κB activation, and thus lowering the expression of proinflammatory mediators.

High-fat diet-fed WT mice show crown-like structures formed by macrophages surrounding dying adipocytes in visceral adipose tissue [23, 24]. The expression of proinflammatory cytokines in these infiltrated macrophages is increased by TLR4, which is stimulated by intracellular components such as free fatty acids released from hypertrophied adipocytes [31, 32]. In OPG-/- mice, high levels of circulating RANKL are free to bind to RANK, promoting its activation [10, 11]. And we have previously reported that OPG-/- mice show browning of subcutaneous and visceral adipose tissue and that RANKL stimulates beige adipocyte differentiation into beige adipocytes [11]. Moreover, macrophages infiltrated in the visceral adipose tissue of OPG-/- mice under a high-fat diet showed lower expression of iNOS when compared to those of WT mice [11]. In this study, we observed no macrophage infiltration and no crown-like structure formation in visceral adipose tissue of OPG-/- mice under a high-fat diet for 3 months (Figure 1(a)). In accordance with our previous work [11], we found lower levels of IL-1β in visceral adipose tissue of OPG-/- mice (Figure 1(b)), which reinforces the observation of lower inflammation in adipose tissue of OPG-/- mice, when compared to controls. Macrophages cultivated in adipose tissue-conditioned medium (ATCM) with RANKL showed lower expression of proinflammatory mediators such as iNOS, IL-1β, and TNF-α (Figures 1(c)–1(g)).
Together, these data suggest that by binding RANK, RANKL reduces inflammation in adipose tissue and macrophages. The adipose tissue-conditioned medium contains large amounts of saturated fatty acids recognized by TLR4 [33] and many unknown components. LPS is considered the classical activator of TLR4; it elicits a proinflammatory response in macrophages, such as the expression and secretion of critical proinflammatory mediators such as IL-1β, TNF-α, and iNOS. In response to IL-1β binding, a complex sequence of phosphorylation and ubiquitination events leads to activation of NF-κB, JNK, and p38 MAPK pathways, which together induce the expression of target genes such as IL-6, IL-8, and MCP-1, that further amplify the proinflammatory response [34–36]. TNF-α binds to the receptor TNFR1, which belongs to a group of death receptors (DR) containing death domains (DD) associated with a cytoplasmic silencer of the death domain (SODD) in the resting state [37]. Upon TNF-α activation, SODD is released, and the DD domain of TNFR1 can interact with other adaptor proteins that activate transcription factors such as NF-κB and AP-1, which increase the expression of cytokines, adhesive molecules, and metalloproteinases, for example [38]. LPS stimulation also increases iNOS levels, an enzyme that triggers NO synthesis, which acts as a cytotoxic effector molecule with antimicrobial activity in macrophages and damages normal cells. These proinflammatory mediators released by macrophages upon LPS stimulation are also found in adipose tissue inflammation induced by obesity [39]. In high-fat diet mice, adipose tissue macrophages show increased expression of genes essential for macrophage migration, phagocytosis, proinflammatory cytokines such as IL-6, IL-1β, and TNF-α, and iNOS [39, 40], which induces a low-grade proinflammatory state. TNF-α downregulates perilipin (PLIN) expression, a small protein that coats the intracellular triglyceride lipid droplet in white adipocytes, regulating lipolysis rate and adipocyte fatty acid secretion. Hence, TNF-α increases lipolysis in human and lineage adipocytes [41, 42]. In this context, macrophages are recruited by adipocyte components released during lysis of hypertrophied cells, such as free fatty acids, capable of activating TLR4 to produce proinflammatory cytokines in macrophages, which favors TNF-α-induced lipolysis and more TLR4 activation [18].

Thus, to confirm the findings observed with adipose tissue-conditioned medium stimulation, macrophages were costimulated with LPS+RANKL to assess the effect of RANKL-induced RANK stimulation on the TLR4 pathway activation. Based on our observation that in the presence of RANKL, expressions of LPS-induced factors TNF-α, IL-1β, and iNOS are reduced (Figures 2(a)–2(g)), we propose that the anti-inflammatory property of RANKL is through inhibition of TLR4 activation. Macrophages pretreated for 6 h or 24 h with RANKL showed reduced TLR4 activation under LPS stimulation due to lower mRNA expression of adaptor proteins that participate in the TLR4 signaling transduction pathway [19]. Here, macrophages submitted to stimulation with LPS+RANKL showed no difference regarding the expression of the mRNAs of adaptor proteins such as Myd88, IRAK, and TRAF6 (data not shown) after 6 h or 24 h of costimulation, even though we did observe lower expression of IL-1β and TNF-α during this same time course (Figures 2(a) and 2(b)). Thus, this data indicates that RANKL stimulation inhibited events in the TLR4 pathway occurring upstream of the expression of proinflammatory cytokines.
The TLR4 pathway culminates in the activation of several transcription factors [43]. NF-κB activation is crucial for LPS-induced proinflammatory cytokine expression [44]. In other scenarios, RANKL has been reported to increase NF-κB activation as a proinflammatory response in the liver and pancreas [45]. Even though RANKL is named for receptor activator of NF-κB ligand, RANKL-induced NF-κB activation is not always related to inflammatory cell response. For example, RANKL was first identified in bone and named ODF (osteoclast differentiation factor) [46] because it induces osteoclast activation and bone resorption by activating the transcription factors NF-κB and NFATc [47, 48]. Additionally, RANKL was found to activate RANK (and named for receptor activator of NFκB) in dendritic cells, in which RANKL increases the ability to stimulate T cells [49, 50]. In this study, we show that RANKL does not change IL-1β, TNF-α, or iNOS expression levels in macrophages nor it significantly changes the NF-κB activation in macrophages, as shown by the luciferase reporter assay (Figure 2(h)).

TRAF6 is a common adaptor protein in both TLR4 and RANK pathways [20, 51, 52] and is activated upstream the NF-κB nuclear translocation in the TLR4 pathway. RANKL stimulation increased colocalization of RANK and TRAF6, as detected by confocal microscopy, in the LPS+RANKL stimulated group when compared to the LPS group (Figures 3(a) and 3(b)). Protein extracts from macrophages treated with RANKL, LPS, and LPS+RANKL were analyzed for endogenous TRAF6 interaction with RANK or TLR4 by co-immunoprecipitation. We observed that RANK co-

![Figure 5: RANKL downregulates the pathways related to chemotaxis in BMDM. (a) MA plot for log2 folds changes values against normalized counts for each gene in the analysis. Red points mark genes with FDR < 0.1. (b) Visualization as a heat map of genes that are up- and downregulated in BMDM without (CT) or with RANKL stimulation (10 ng/ml) (RANKL) for 24 h.](image-url)
immunoprecipitated with TRAF6 in cells treated with RANKL and LPS+RANKL, but not in cells stimulated with LPS only (Figure 3(c)). These findings indicate that in the presence of RANKL, TRAF6 binds to RANK, even if LPS is present. LPS treatment promotes the binding between TLR4 and TRAF6, a reason why we observed higher levels of TLR4/TRA6 co-immunoprecipitation. However, this is not observed when cells are stimulated with LPS+RANKL (Figure 3(d)), given by the presence of TRAF6 in the pull-down (Figure 3(e)). These data indicate that RANKL impairs TLR4 activation by promoting TRAF6 interaction with RANK. These findings indicate that in the presence of LPS, RANKL stimulation promotes TRAF6 interaction with RANK while decreasing TRAF6 interaction with TLR4.

Macrophages overexpressing a version of RANK carrying a point mutation in the domain of TRAF6-binding sites presented similar levels of IL-1β and TNF-α expression in LPS+RANKL groups as those observed in the LPS group (Figures 4(c) and 4(d)). These findings suggest that RANK interaction with TRAF6 is crucial for RANKL inhibition of TLR4-induced gene expression.

TRAF6 is an ubiquitin E3 ligase that catalyzes lysine-63 (K63) polyubiquitination in target proteins such as 1kB kinase or as a self-polyubiquitination of TRAF6, which in turn forms a recognition signal for the recruitment of proteins such as TAB2/3 and TAK1, leading to NF-κB activation. TRAF6 can also be modified by K48-linked ubiquitination that targets proteasome degradation [53–55]. Therefore, future analysis should investigate if RANKL stimulation routes TRAF6 to degradation by increasing TRAF6-K48 ubiquitination in macrophages and blocking the inflammatory process.

Global analysis of gene expression by RNA-seq showed that RANKL stimulation induced a differential expression of 376 transcripts in macrophages (Figure 5(a)), downregulating the expression of genes such as Ccl6, Ccl7, and Ccr2, which are related to chemotaxis of proinflammatory macrophages (Figure 5(b)) [56–58]. Although Tnfsf13b was upregulated, which is related to osteoclastogenesis [30], the macrophages stimulated with RANKL showed no osteoclastogenesis (data not shown). This finding indicates that RANKL lowers the expression of target genes involved in chemotaxis besides the impairment of TLR4 activation. Further studies are necessary to clarify how the binding between TRAF6 and RANK results in sustained inhibition of NF-κB activation in macrophages.

It should be noted that the experiments performed here were restricted to THP1 macrophages, immortalized human monocyte, and BMDMs from wild-type mice. In addition, the effect of RANKL was not evaluated in macrophages in inflammatory contexts in animals or patients. Therefore, the interpretation of these results may be limited, and future studies are warranted in human macrophages under a chronic low-grade inflammatory state found in obesity or acute inflammation such as septic shock, for example.

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that developed into coronavirus disease 2019 (COVID-19) can lead to respiratory failure and death in patients. A growing body of clinical studies suggests that a cytokine storm triggered by the viral infection is associated with COVID-19 severity and is also a crucial cause of death in this disease [59, 60]. Retrospective studies have shown that obesity is an independent risk factor for complications in COVID-19, and it suggests that the chronic inflammation induced in the adipose tissue can increase the risk for cytokine storm [61–63]. Thus, RANKL could be a potential candidate for drug development to mitigate the impact of obesity-induced inflammation in patients.

5. Conclusions

This study shows for the first time that RANKL increases TRAF6 interaction with RANK to the detriment of TLR4 and decreases proinflammatory responses in macrophages. It also provides new insights on the role of RANKL in inflammatory processes in macrophages elicited by TLR4 activation and suggests that high OPG levels found in obese patients or under septic shock could be considered a poor prognostic in part because OPG may aggravate inflammation by inhibiting RANKL.

Data Availability

Data is available under request to the corresponding author (Mariana Kiomy Osako, mko@fmrp.usp.br).

Conflicts of Interest

The authors declare no conflict of interest.

Authors’ Contributions

R.F.M was responsible for the investigation, methodology, validation, writing the original draft, and formal analysis. P.H.C.A. was responsible for the methodology and formal analysis. M.E.R.C., F.S.M., and R.J.M.M. were responsible for the methodology. C.A.O.B.J and K.C.P. were responsible for the RNA-seq methodology and analysis. H.H., M.S., and H.N. were responsible for the formal analysis. M. K. O. was responsible for the conceptualization, investigation, methodology, review and editing of the manuscript, supervision, and funding acquisition.

Acknowledgments

We are grateful to Marcia Triunfol at Publiclace for reviewing this manuscript, Silvia Regina Andrade Nascimento for her technical assistance, and the Institute for Cancer Research (IPEC) for providing the infrastructure for bioinformatics analysis. This work was supported by the Sao Paulo Research Foundation (FAPESP) (grant numbers 2014/11092-6, 2016/00308-2, 2016/00651-0, 2016/22009-8, 2016/21579-5, and 2015/26088-7), National Council for Scientific and Technological Development Research (CNPq), and Foundation for Support to Teaching, Research and Assistance of Clinical Hospital of Ribeirao Preto Medical School of University of Sao Paulo (FAEPA-HCFMRP-USP).
References

[1] C. N. Lumeng, J. B. DelProposto, D. J. Westcott, and A. R. Saltiel, "Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes," *Diabetes*, vol. 57, no. 12, pp. 3239–3246, 2008.

[2] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante, "Obesity is associated with macrophage accumulation in adipose tissue," *Journal of Clinical Investigation*, vol. 112, no. 12, pp. 1796–1808, 2003.

[3] H. Kanda, S. Tateya, Y. Tamori et al., "MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity," *Journal of Clinical Investigation*, vol. 116, no. 6, pp. 1494–1505, 2006.

[4] M. Holecki, B. Zahorska-Markiewicz, J. Janow ska et al., "The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women," *Obesity*, vol. 15, no. 8, pp. 1925–1929, 2007.

[5] P. Secchiero, F. Corallini, A. Pandolfo et al., "An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction," *The American Journal of Pathology*, vol. 169, no. 6, pp. 2236–2244, 2006.

[6] M. Schaan and W. Mohamed, "Predictive ability of circulating osteoprotegerin as a novel biomarker for early detection of acute kidney injury induced by sepsis," *European Cytokine Network*, vol. 28, no. 2, pp. 52–62, 2017.

[7] H. Kemperman, I. T. Schrijver, M. Roest, J. Keseciogl u, W. W. van Solinge, and D. W. de Lange, "Osteoprotegerin is higher in sepsis than in noninfectious SIRS and predicts 30-day mortality of SIRS patients in the intensive care," *The Journal of Applied Laboratory Medicine*, vol. 3, no. 4, pp. 559–568, 2019.

[8] T.-J. Song, J. Kim, S.-H. Yang et al., "Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients," *Biomarkers*, vol. 17, no. 8, pp. 738–744, 2012.

[9] J. Wajda, M. Swiat, A. J. Owczarek et al., "Osteoprotegerin assessment improves prediction of mortality in stroke patients," *Journal of Stroke and Cerebrovascular Diseases*, vol. 28, no. 5, pp. 1160–1167, 2019.

[10] N. Bucay, I. Sarosi, C. R. Dunstan et al., "Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification," *Genes & Development*, vol. 12, no. 9, pp. 1260–1268, 1998.

[11] F. S. Matsuo, P. H. Cavalcanti, R. de Araújo et al., "RANKL induces beige adipocyte differentiation in preadipocytes," *American Journal of Physiology. Endocrinology and Metabolism*, vol. 318, no. 6, pp. E866–E877, 2020.

[12] M. Shimamura, H. Nakagami, M. K. Osako et al., "OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice," *Proceedings of the National Academy of Sciences*, vol. 111, no. 22, pp. 8191–8196, 2014.

[13] P. J. Murray, J. E. Allen, S. K. Biswas et al., "Macrophage activation and polarization: nomenclature and experimental guidelines," *Immunity*, vol. 41, no. 1, pp. 14–20, 2014.

[14] C. F. Nathan, H. W. Murray, M. E. Wiebe, and B. Y. Rubin, "Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and anti-microbial activity," *Journal of Experimental Medicine*, vol. 158, no. 3, pp. 670–689, 1983.

[15] K. Hoshino, O. Takeuchi, T. Kawai et al., "Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product," *The Journal of Immunology*, vol. 162, no. 7, pp. 3749–3752, 1999.

[16] B. Verstak, K. Nagpal, S. P. Bottomley, D. T. Golenbock, P. J. Hertzog, and A. Mansell, "MyD88 adapter-like (Mal)/TRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-KB proinflammatory responses," *Journal of Biological Chemistry*, vol. 284, no. 36, pp. 24192–24203, 2009.

[17] M. Yu, H. Wang, A. Ding et al., "HMGB1 signals through toll-like receptor (TLR) 4 and TLR2," *Shock*, vol. 26, no. 2, pp. 174–179, 2006.

[18] H. Shi, M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S. Flier, "TLR4 links innate immunity and fatty acid–induced insulin resistance," *Journal of Clinical Investigation*, vol. 116, no. 11, pp. 3015–3025, 2006.

[19] K. Maruyama, Y. Takada, N. Ray et al., "Receptor activator of NF-KB ligand and osteoprotegerin regulate proinflammatory cytokine production in mice," *The Journal of Immunology*, vol. 177, no. 6, pp. 3799–3805, 2006.

[20] A. P. Armstrong, M. E. Tometsko, M. Glaccum, C. L. Sutherland, D. Cosman, and W. C. Dougall, "A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function," *Journal of Biological Chemistry*, vol. 277, no. 46, pp. 44347–44356, 2002.

[21] S. Thalmann, C. E. Juge-Aubry, and C. A. Meier, "Explant cultures of white adipose tissue," *Methods in Molecular Biology*, vol. 456, 2008.

[22] V. Zinchuk, O. Zinchuk, and T. Okada, "Quantitative Colocalization analysis of multicolor confocal immunofluorescence microscopy images: pushing pixels to explore biological phenomena," *Acta Histochemica et Cytochemica*, vol. 40, no. 4, pp. 101–111, 2007.

[23] M. M. Altintas, A. Azad, B. Nayer et al., "Mast cells, macrophages, and crown-like structures distinguish subcutaneous from visceral fat in mice," *Journal of Lipid Research*, vol. 52, no. 3, pp. 480–488, 2011.

[24] I. Murano, G. Barbatelli, V. Parisiani et al., "Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice," *Journal of Lipid Research*, vol. 49, no. 7, pp. 1562–1568, 2008.

[25] B. G. Darnay, J. Ni, P. A. Moore, and B. B. Aggarwal, "Activation of NF-KB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-KB-inducing kinase," *Journal of Biological Chemistry*, vol. 274, no. 12, pp. 7724–7731, 1999.

[26] H. Ye, J. R. Arron, B. Lamothe et al., "Distinct molecular mechanism for initiating TRAF6 signalling," *Nature*, vol. 418, no. 6896, pp. 443–447, 2002.

[27] R. Buccafusca, C. P. Venditti, L. C. Kenyon et al., "Characterization of the null murine sodium/myo-inositol cotransporter 1 (Slm1 or Slc5a3) phenotype: myo-inositol rescue is independent of expression of its cognate mitochondrial ribosomal protein subunit 6 (Mrps6) gene and of phosphatidylinositol levels in neonatal brain," *Molecular Genetics and Metabolism*, vol. 95, no. 1–2, pp. 81–95, 2008.

[28] Q. Huang, W. Yuan, X. Wei, W. He, X. Liu, and J. Ye, "Evolutionary analysis of voltage-gated potassium channels by Bayes method," *Journal of Molecular Neuroscience*, vol. 53, no. 1, pp. 41–49, 2014.
C. N. Lumeng, S. M. DeYoung, J. L. Bodzin, and A. R. Saltiel, “Bone morphogenetic protein (BMP)1-3 enhances bone repair,” Biochemical and Biophysical Research Communications, vol. 408, no. 1, pp. 25–31, 2011.

R.-W. Wu, W.-S. Lian, Y.-S. Chen et al., “MicroRNA-29a counteracts glucoconcentric induction of bone loss through repressing TNFSF13b modulation of osteoclastogenesis,” International Journal of Molecular Sciences, vol. 20, no. 20, p. 5141, 2019.

K. B. Cullberg, J. Ø. Larsen, S. B. Pedersen, and B. Richelsen, “Effects of LPS and dietary free fatty acids on MCP-1 in 3T3-L1 adipocytes and macrophages in vitro,” Nutrition & Diabetes, vol. 4, no. 3, pp. e113–e113, 2014.

H. Holmström, J. Enninga, S. Kälble et al., “The MAPK kinase kinase TAK1 plays a central role in coupling the interleukin-1 receptor to both transcriptional and RNA-targeted mechanisms of gene regulation,” Journal of Biological Chemistry, vol. 276, no. 5, pp. 3508–3516, 2001.

H. Holmström, R. Winzen, P. Holland et al., “Induction of interleukin-8 synthesis integrates effects on transcription and MRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways,” Molecular and Cellular Biology, vol. 19, no. 10, pp. 6742–6753, 1999.

S. Saccani, S. Pantano, and G. Natoli, “P38-dependent marking of inflammatory genes for increased NF-KB recruitment,” Nature Immunology, vol. 3, no. 1, pp. 69–75, 2002.

J. Bradley, “TNF-mediated inflammatory disease,” The Journal of Pathology, vol. 214, no. 2, pp. 149–160, 2008.

Y. Jiang, J. D. Woronicz, W. Liu, and D. V. Goeddel, “Prevention of constitutive TNF receptor 1 signaling by silencer of death domains,” Science, vol. 283, no. 5401, pp. 543–546, 1999.

C. N. Lumeng, J. L. Bodzin, and A. R. Saltiel, “Obesity induces a phenotypic switch in adipose tissue macrophage polarization,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 175–184, 2007.

C. N. Lumeng, S. M. DeYoung, J. L. Bodzin, and A. R. Saltiel, “Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity,” Diabetes, vol. 56, no. 1, pp. 16–23, 2007.

M. Rydén, E. Arvidsson, L. Blomqvist, L. Perbeck, A. Dicker, and P. Arner, “Targets for TNF-a induced lipolysis in human adipocytes,” Biochemical and Biophysical Research Communications, vol. 318, no. 1, pp. 168–175, 2004.

S. C. Souza, L. Moitso, M. T. de Vargas et al., “Overexpression of perilipin A and B blocks the ability of tumor necrosis factor a to increase lipolysis in 3T3-L1 adipocytes,” Journal of Biological Chemistry, vol. 273, no. 38, pp. 24665–24669, 1998.

V. Toshchakov, B. W. Jones, P.-Y. Perera et al., “TLR4, but not TLR2, mediates IFN-β-induced STAT1α/β-dependent gene expression in macrophages,” Nature Immunology, vol. 3, no. 4, pp. 392–398, 2002.

Y.-C. Lu, W.-C. Yeh, and P. S. Ohashi, “LPS/TLR4 signal transduction pathway,” Cytokine, vol. 42, no. 2, pp. 145–151, 2008.

S. Kiechl, J. Wittmann, A. Giaccari et al., “Blockade of receptor activator of nuclear factor-KB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus,” Nature Medicine, vol. 19, no. 3, pp. 358–363, 2013.

H. Yasuda, N. Shima, N. Nakagawa et al., “Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL,” Proceedings of the National Academy of Sciences, vol. 95, no. 7, pp. 3597–3602, 1998.

T. L. Burgess, Y.-x. Qian, S. Kaufman et al., “The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts,” Journal of Cell Biology, vol. 145, no. 3, pp. 527–538, 1999.

N. Takahashi, N. Udagawa, and T. Suda, “A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function,” Biochemical and Biophysical Research Communications, vol. 256, no. 3, pp. 449–455, 1999.

D. M. Anderson, E. Maraskovsky, W. L. Billingsley et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function,” Nature, vol. 390, no. 6656, pp. 175–179, 1997.

K. Loser, A. Mehlng, S. Loser et al., “Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells,” Nature Medicine, vol. 12, no. 12, pp. 1372–1379, 2006.

B. G. Darnay, A. Besse, A. T. Poblenz, B. Lamothe, and J. J. Jacoby, “TRAFs in RANK signaling,” Advances in Experimental Medicine and Biology, vol. 597, pp. 152–159, 2007.

B. Lamothe, W. K. Webster, A. Gopinathan, A. Besse, A. D. Campos, and B. G. Darnay, “TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation,” Biochemical and Biophysical Research Communications, vol. 359, no. 4, pp. 1044–1049, 2007.

B. Lamothe, A. D. Campos, W. K. Webster, A. Gopinathan, L. Hur, and B. G. Darnay, “The RING domain and first zinc finger of TRAF6 coordinate signaling by interleukin-1, lipopolysaccharide, and RANKL,” The Journal of Biological Chemistry, vol. 283, no. 36, pp. 24871–24880, 2008.

B. Skaug, X. Jiang, and Z. J. Chen, “The role of ubiquitin in NF-KB regulatory pathways,” Annual Review of Biochemistry, vol. 78, no. 1, pp. 769–796, 2009.

L. Sun, L. Deng, C.-K. Ea, Z.-P. Xia, and Z. J. Chen, “The TRAF6 ubiquitin ligase and TAK1 kinase mediate IFK activation by BCL10 and MALT1 in T lymphocytes,” Molecular Cell, vol. 14, no. 3, pp. 289–301, 2004.

P. M. Brunner, E. Glitzner, B. Reininger et al., “CCL7 contributes to the TNF-alpha-dependent inflammation of lesional psoriatic skin,” Experimental Dermatology, vol. 24, no. 7, pp. 522–528, 2015.

A. M. LaFleur, N. W. Lukacs, S. L. Kunkel, and A. Matsukawa, “Role of CC chemokine CCL6/C10 as a monocyte chemoattractant in a murine acute peritonitis,” Mediators of Inflammation, vol. 13, 355 pages, 2004.

S. Willenborg, T. Lucas, G. van Loo et al., “CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair,” Blood, vol. 120, no. 3, pp. 613–625, 2012.
[59] D. Blanco-Melo, B. E. Nilsson-Payant, W.-C. Liu et al., “Imbalanced host response to SARS-CoV-2 drives development of COVID-19,” Cell, vol. 181, no. 5, pp. 1036–1045.e9, 2020.

[60] B. Zhang, X. Zhou, Y. Qiu et al., “Clinical characteristics of 82 cases of death from COVID-19,” PLOS ONE, vol. 15, no. 7, article e0235458, 2020.

[61] P. Goyal, J. B. Ringel, M. Rajan et al., “Obesity and COVID-19 in New York City: a retrospective cohort study,” Annals of Internal Medicine, vol. 173, no. 10, pp. 855–858, 2020.

[62] S. Richardson, J. S. Hirsch, M. Narasimhan et al., “Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area,” JAMA, vol. 323, no. 20, pp. 2052–2059, 2020.

[63] N. Sattar, F. K. Ho, J. M. R. Gill et al., “BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: preliminary findings from UK biobank,” Diabetes and Metabolic Syndrome: Clinical Research and Reviews, vol. 14, no. 5, pp. 1149–1151, 2020.